Humana (HUM)
(Delayed Data from NYSE)
$305.90 USD
-5.51 (-1.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $306.06 +0.16 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Humana (HUM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$396.72 | $579.00 | $310.00 | 27.39% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Humana comes to $396.72. The forecasts range from a low of $310.00 to a high of $579.00. The average price target represents an increase of 27.39% from the last closing price of $311.41.
Analyst Price Targets (18)
Broker Rating
Humana currently has an average brokerage recommendation (ABR) of 2.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 42.11% and 5.26% of all recommendations. A month ago, Strong Buy made up 47.37%, while Buy represented 5.26%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 9 | 9 | 11 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 9 | 9 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.11 | 2.00 | 2.00 | 1.72 | 1.72 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Cantor Fitzgerald & Co | Sarah James | Hold | Hold |
3/22/2024 | Raymond James | John W Ransom | Hold | Hold |
3/12/2024 | Argus Research Corp. | David A Toung | Strong Buy | Hold |
1/26/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
1/19/2024 | Truist Securities | David S Macdonald | Hold | Hold |
11/3/2023 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
11/1/2023 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.11 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 19 |
Average Target Price | $391.61 |
LT Growth Rate | 10.60% |
Industry | Medical - HMOs |
Industry Rank by ABR | 203 of 252 |
Current Quarter EPS Est: | 5.86 |